Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 43 Show results per page	View Search Criteria \| Help With Results

Last Modified: 2/21/2007 First Published: 2/10/2006


1.		Phase I/II Study of ZD6474 in Patients With Recurrent High-Grade or Progressive Low-Grade Gliomas

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				NCI-06-C-0063 NCI-P6680, NCT00293566

Last Modified: 8/13/2008 First Published: 8/3/2007


2.		Phase I/II Study of Vandetanib in Young Patients With Hereditary Medullary Thyroid Carcinoma

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Biomarker/Laboratory analysis, Treatment				Active				5 to 18				NCI				NCI-07-C-0189 07-C-0189, NCT00514046

Last Modified: 10/27/2008 First Published: 8/8/2008


3.		Phase I/II Randomized Study of Vandetanib, Oxaliplatin, and Docetaxel in Patients With Advanced Cancer of the Esophagus or Gastroesophageal Junction

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				NCI				CASE-6507 CASE6507, SANOFI-AVENTIS-CASE-6507, NCT00732745


4.		Radiation Therapy (XRT)and ZD6474 in Non-Small Cell Lung Cancer (NSCLC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II, Phase I				Treatment				Active				18 and over				Other				2003-0787 NCT00745732

Last Modified: 6/10/2008 First Published: 9/3/2004


5.		Phase II Randomized Study of ZD6474, Carboplatin, and Paclitaxel in Patients With Previously Untreated Stage IIIB or IV or Recurrent Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				NCI, Pharmaceutical / Industry				UCLA-0405022-01 ZENECA-D4200C00007, ZENECA-D4200C007A, NCT00093392


6.		BATTLE Program: ZD6474 in Previously Treated Subjects With NSCLC

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2005-0825 NCT00410189


7.		Docetaxel in Combination With Zactima (ZD6474) in Patients With Locally Advanced Squamous Cell Carcinoma of the the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				06-283 NCT00459043


8.		Malignant Pleural Effusion With ZD6474

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				2005-0929 NCT00402896


9.		Phase II Anastrozole and ZD6474 in Neoadjuvant Treatment of Postmenopausal Hormone Receptor-Positive Breast Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				18 and over				Other				BRSADJ0008 97923, BRSADJ0008, NCT00481845, NCT00481845


10.		Phase II Study of Best Support Care (BSC) Plus ZD6474 in Patients With Inoperable Hepatocellular Carcinoma (HCC)

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Active				20 to 120				Pharmaceutical / Industry				D4200C00072 NCT00508001

Select All on One Page


					1 2 3 4 Next >

| | | | | | | |

A Service of the National Cancer Institute